News on research and diagnostic development for pathogenic diseases.
The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent.
The company plans to expand into new markets through its recent acquisition of Alere Triage assets.
The CE-marked test enables health professionals to distinguish between HIV-1 and HIV-2, and runs on the fully automated Cobas 6800/8800 systems.
The Inhale project is assessing respiratory disease tests on Oxford Nanopore's MinIon and PCR platforms from Curetis and BioMérieux's BioFire Diagnostics.
The fourth test for which the firm has received regulatory clearance this year takes aim at a common microbial cause of healthcare-associated infections.
